How Can Erythropoeitin-Stimulating Agent Use be Reduced in Chronic Dialysis Patients?
Can Reduction of Inflammation Improve ESA Dose Response?
Address correspondence to: Csaba P Kovesdy, MD FASN, Division of Nephrology, Memphis VA Medical Center, 1030 Jefferson Ave., Memphis, TN 38104, Tel.: 901-577-7278, Fax: 901-577-7539, or e-mail: email@example.com
No abstract is available for this article.